AEON Biopharma (AEON) vs BioCardia (BCDA)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
BioCardia (BCDA) has outperformed AEON Biopharma (AEON) over the past year, losing 25.4% versus a loss of 66.3%. BioCardia is the larger company by market cap ($16.0 million vs $15.5 million), about 1.0 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | AEON | BCDA |
|---|---|---|
| Share price | $0.31 | $1.06 |
| Market cap | $15.46M | $16.05M |
| 1-day change | -0.40% | -2.75% |
| YTD return | -71.82% | -15.20% |
| 1-year return | -66.30% | -25.35% |
| 5-year return | — | -97.59% |
| EPS (TTM) | $-4.39 | $-0.64 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $1.45 | $1.80 |
| 52-week low | $0.177 | $0.75 |
| Distance from 52-week high | -78.62% | -41.11% |
| Analyst consensus | strong_buy | none |
| Avg. price target upside | +487.10% | +1362.26% |
| Average volume | 8.59M | 282.05K |
| Shares outstanding | 49.88M | 15.14M |
| Employees | 8 | 17 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
Key differences
- BCDA has outperformed AEON by 41.0 percentage points over the past year.
About AEON Biopharma
AEON stock →AEON Biopharma, Inc., a clinical stage biopharmaceutical company, focuses on developing botulinum toxins. It develops ABP-450 (prabotulinumtoxinA) injection for debilitating medical conditions, which completed Phase 2 study for the treatment of cervical dystonia and has an ongoing Phase 2 study for the treatment of chronic and episodic migraine.
Healthcare · Biotechnology · 8 employees
About BioCardia
BCDA stock →BioCardia, Inc., a clinical-stage regenerative medicine company, develops cellular and cell-derived therapeutics for cardiovascular and pulmonary diseases in the United States. The company's lead product candidate is CardiAMP, an autologous mononuclear cell therapy system in Phase III clinical trial for the treatment of ischemic heart failure with reduced ejection fraction and refractory angina resulting from chronic myocardial ischemia.
Healthcare · Biotechnology · 17 employees
AEON vs BCDA FAQ
Which is bigger, AEON Biopharma or BioCardia?
BioCardia (BCDA) is larger, with a market capitalization of $16.05M compared with $15.46M for AEON Biopharma (AEON).
Which stock has performed better over the past year, AEON or BCDA?
BCDA returned -25.35% over the past 12 months, compared with -66.30% for AEON (price return, excluding dividends). Past performance does not predict future results.
Are AEON Biopharma and BioCardia in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.